J&J in deal to develop microbiome drug for bowel diseases

January 13, 2015 1:01 PM

17 0

Jan 13 (Reuters) - Johnson & Johnson on Tuesday announced a licensing deal with Vedanta Biosciences to develop the privately held company's lead microbiome-based drug candidate for inflammatory bowel disorders, such as Crohn's disease and ulcerative colitis.

J&J said Vedanta will receive an undisclosed upfront payment and would be eligible to receive up to $241 million for achieving development and commercial milestones.

Also read: Michigan State to Pay Victims of Larry Nassar Abuse $500 Million

Read more

To category page